Clinical Trial Detail

NCT ID NCT02530476
Title Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic/myeloproliferative neoplasm

acute myeloid leukemia

bone marrow cancer

Therapies

Selinexor + Sorafenib

Age Groups: adult

Additional content available in CKB BOOST